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Summary
Objective: To investigate the gene expression proﬁle and the histological aspects of articular cartilage of patients affected by Morquio
syndrome, a lysosomal storage disease characterized by the accumulation of glycosaminoglycans within the cells which result in abnormal
formation and growth of the skeletal system.
Method: Articular cartilage samples were obtained from the femoral condyle of two siblings with Morquio syndrome during surgery per-
formed to treat valgus knee. As controls, four biopsy samples of healthy cartilage were obtained from four different male multiorgan do-
nors. A Real-Time Polymerase Chain reaction (RT-PCR) analysis was performed to evaluate the expression of type I and II collagens
and aggrecan mRNAs. Histological and immunohistochemical analyses for some matrix proteins were carried out on parafﬁn embedded
sections.
Results: Type I collagen mRNA mean level was higher in the samples of patients with Morquio syndrome compared to controls. Type II col-
lagen and aggrecan mRNAs’ mean expression was instead lower. The morphological appearance of the cartilage showed a poorly organized
tissue structure with not homogeneously distributed cells that were larger compared to normal chondrocytes due to the presence inside the
vacuoles of proteoglycans which were not metabolized. Chondrocytes were negative for collagen II immunostaining while the extracellular
matrix was weakly positive. Collagen type I immunostaining was positive at cellular level. Keratan sulfate showed diffuse positivity and
chondroitin-6-sulfate was present throughout the cartilaginous thickness.
Conclusion: In cartilage of patients with Morquio syndrome, a low expression of collagen type II and a high expression of collagen type I both
at protein and molecular levels are evidentiated. This ﬁnding could give evidence of the reduction in ankle and knee joint movement observ-
able in these patients.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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SocietyIntroduction
Morquio syndrome, also known as MorquioeBrailsford syn-
drome belongs to mucopolysaccharidoses. It was so called
by the physician who ﬁrst described this pathology in
a Swedish family1,2. Also called mucopolysaccharidosis
type IV A (MPS IV A), it is an autosomal recessive inborn
error resulting from the deﬁcient activity of the lysosomal
enzyme N-acetylgalactosamine-6-sulfatase (GALNS)3e5.
From a biochemical point of view MPS IV A is different
from type B which is caused by the deﬁciency of the
b-galactosidase enzyme6,7. GALNS is one of the sulfatases
required to degrade glycosaminoglycans, such as keratan
sulfate and chondroitin-6-sulfate8. To date, over 90
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70 missense mutations. Genotype/phenotype correlation
exists for some of these mutations; most deletions lead to
the severe form of MPS IV A, while point mutations produce
a broad range of phenotypes9e12. These vary from the clas-
sical form with bone dysplasia, spinal deformity, cardiac
abnormalities, corneal opacities, deafness and dental ab-
normalities to attenuated forms with fewer manifestations13.
Compared to other types of mucopolysaccharidoses, vis-
ceral organs and mental development in Morquio disease
are normal. There are very few data in the literature report-
ing histological and/or molecular evaluations in this pathol-
ogy. Some arthroscopy ﬁndings suggest that pathologic
alterations are at the cartilageebone junction14. We had
the opportunity to receive biopsies from two brothers with
Morquio syndrome who had undergone surgery to correct
valgus knee and we used immunohistochemical analyses
to look at the morphological aspect of the cartilage tissue.
We performed, for the ﬁrst time in this pathology, a Real-
Time PCR analysis to evaluate the gene expression proﬁle311
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tissue.
Materials and methods
PATIENTS
Cartilage biopsies were obtained from two siblings (one
man and one woman; 35 and 38 years old, respectively)
affected by the more severe form of Morquio syndrome
as diagnosed at Istituto Giannina Gaslini (Genova, Italy)15.
The patients were both homozygous for the same muta-
tion of the gene which encodes for the GALNS enzyme.
This mutation is responsible for the lack of enzyme activity
through the exon-2 skipping which contains the catalytic
site of the enzyme. It was shown that the proximity of
exon-2 at the mutation site leads to this alternative splic-
ing15. The biopsies were obtained from the femoral con-
dyle of the knee during surgery performed to treat valgus
knee. As controls, four biopsy samples of healthy cartilage
were obtained from four different male multiorgan donors
(aged 20, 47, 35, and 38) who did not have a known his-
tory of arthritis or other joint pathology. Informed consent
was obtained from the patients and the work was ap-
proved by the Ethical Committee of Istituti Ortopedici
Rizzoli.
CHONDROCYTE ISOLATION
The chondrocytes were isolated from the biopsies by
enzymatic procedure as previously reported16. Brieﬂy,
fragments of the cartilaginous tissues were cultured in Dul-
becco’s modiﬁed Eagle’s medium (DMEM) (Life Technolo-
gies, Paisley Scotland) with 25 mM N-(2-Hydroxyethyl)
piperazine-N 0-(2-ethanesulfonic acid); 4-(2-Hydroxyethyl)
piperazine-1-ethanesulfonic acid) (HEPES) (Sigma),
penicillinestreptomycin 10,000 U/ml and 10,000 mg/ml,
respectively (Gibco), and 50 mg/ml gentamycin (Biological
Industries, Kibbutz Beth Haemek, Israel). The chondrocytes
were isolated by sequential enzymatic digestions: 30 min
with 0.1% hyaluronidase (Sigma, St Louis, MO, USA), 1 h
with 0.5% pronase (Sigma) and 1 h with 0.2% collagenase
(Sigma) at 37C. The isolated chondrocytes were ﬁltered by
100 mm and 70 mm sterile nylon mesh ﬁlters to remove cell
raft and matrix debris. The ﬁltrate was then centrifuged for
100 at 1800 rpm and the pellet was washed twice with
DMEM supplemented with 10% fetal calf serum (FCS, Bio-
logical Industries, Kibbutz Beth Haemek, Israel). The cellnumber and viability were assessed by vital staining with
eosin.
ANALYSIS OF CARTILAGE-SPECIFIC MOLECULE EXPRESSION
BY REAL-TIME RT-PCR
RNA extraction and reverse transcriptase
5 105 isolated cells were pelleted and lysed in 0.5 ml of
RNAzol B reagent (Biotecx Laboratories, Houston, TX,
USA); total RNA was subsequently isolated according to
the manufacturer’s instructions. Complementary DNA was
synthesized from 1 mg of total RNA per sample with
45 min incubation at 42C, using Moloney murine leukemia
virus reverse transcriptase (Perkin Elmer, Norwalk, CT,
USA) and oligo-(dT) priming.
Primer design
PCR primer for the housekeeping gene glyceraldehyde-
3-phosphate dehydrogenase (GAPDH), used as an internal
control was obtained from published Refs.17e19. PCR
primers for types I and II and aggrecan were designed using
the PRIMER 3 software (Steve Rozen, Helen J, Skaletsky
1998 Primer 3) http://www.genome.wy.mit.edu/genome_
software/other/primer3.html. Speciﬁc primer pairs, PCR
products’ length, annealing temperatures and references
are reported in Table I.
LightCycler Real-Time PCR
Real-Time PCR was run in triplicate in a LightCycler In-
strument (Roche, Applied Science) using the QuantiTect
SYBR Green PCR Kit (Qiagen, GmbH, Germany) with
the following protocol: initial activation of HotStarTaq
DNA Polymerase at 94C for 15 min, 45 cycles of 94C
for 15 s, 56e60C for 20 s and 72C for 10 s.
To determine absolute mRNA copy numbers, standard
curves were generated for collagens I and II and aggrecan
using 10-fold dilution series of gel-puriﬁed PCR products.
The increase in PCR product was monitored for each ampli-
ﬁcation cycle by measuring the increase in ﬂuorescence
caused by the binding of SYBR Green I dye to dsDNA.
The crossing point values (i.e., the cycle number at which
the detected ﬂuorescence exceed the threshold value)
were determined for each standard and sample and speci-
ﬁcity of the amplicons was conﬁrmed by melting curve anal-
ysis. Collagens I and II and aggrecan mRNA levels were
normalized to the housekeeping gene GAPDH.Table I
Real-Time RT-PCR primers’ description
RNA template Primer sequences Amplicon size
(base pairs)
Annealing
temperature ((C)
References*
Aggrecan 50-TCG AGG ACA GCG AGG CC 85 60 PRIMER 3
30-TCG AGG GTG TAG CGT GTA GAG A
Type I collagen 50-AGG TGC TGA TGG CTC TCC T 105 58 PRIMER 3
30-GGA CCA CTT TCA CCC TTG T
Type II collagen 50-GAC AAT CTG GCT CCC AAC 257 58 PRIMER 3
30-ACA GTC TTG CCC CAC TTA C
GAPDH 50-TGG TAT CGT GGA AGG ACT CAT GAC 190 60 17e19
30-ATG CCA GTG AGC TTC CCG TTC AGC
*Primer sequences were obtained from published references where indicated or designed using PRIMER 3 or LightCycler Probe Design
Software.
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Biopsies for histological analysis were ﬁxed in 10%
buffered formalin, washed and decalciﬁed with Formical-
2000 (Decal Chemical, Congers, NY, USA) for 2 h at
room temperature. The samples were then dehydrated
through a graded series of alcohol and embedded in
parafﬁn. Sections, 4 mm thick, were obtained from the car-
tilage specimens, and the slides were stored at room
temperature. The slides were stained with 0.001% Fast
Green and 0.1% Safranin-O (Sigma) and 1% Alcian
Blue 8GX (Sigma).
IMMUNOHISTOCHEMISTRY: TYPE I AND II COLLAGENS
For these immunohistochemical analyses, the following
primary antibodies were used: mouse monoclonal
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Fig. 1. Real-Time PCR analysis of collagens I and II and aggrecan
mRNAs’ expression in chondrocytes isolated from patients with
Morquio syndrome and from controls. Data were normalized to
GAPDH and expressed as mRNA copies/%GAPDH.anti-human type I collagen (Chemicon International, Teme-
cula, CA, USA); anti-human-collagen type II mouse mono-
clonal antibody (Chemicon International). Parafﬁn sections
were deparafﬁnized and rehydrated. For epitope unmasking
the samples were treated with 0.1% hyaluronidase (Sigma)
in phosphate buffered saline (PBS) at 37C for 5 min. After
washes, the slides for the detection of type I and II colla-
gens were incubated at room temperature for 30 min in
1X PBS containing 5% of normal goat serum (NGS)
(Dako, Carpinteria, CA, USA) to prevent non-speciﬁc bind-
ings. The slides were incubated with the anti-human type
I and II collagen primary antibodies diluted 1:20 in 0.04 M
Fig. 2. Representative patient light microscopy evaluation after
Safranin-O staining showing a poorly organized morphological
structure with larger and not homogeneously distributed cells both
in the superﬁcial layer and in the deep zone (A) (bar¼ 200 mm)
compared to normal hyaline cartilage (B) (bar¼ 320 mm).
1314 L. De Franceschi et al.: Molecular and histological aspects of Morquio syndromeFig. 3. Immunostaining for collagen type II in cartilage from a patient with Morquio disease shows a weak positivity which is conﬁned to the
extracellular matrix of both the superﬁcial layer (A) (bar¼ 200 mm) and the deep zone while the cells are negative (B) (bar¼ 500). The
healthy tissue shows a positivity which is evident both for the extracellular matrix (C) (bar¼ 160 mm) and the cells (D) (bar¼ 500). Collagen
type II was developed using new fuchsine (red is positive stain).trizma base saline (TBS) pH 7.6 containing 1% bovine se-
rum albumin (BSA) and 0.1% Triton X-100 for 1 h at room
temperature. The slides were washed three times with
0.04 M TBS pH 7.6 and incubated with goat anti-mouse
and anti-rabbit immunoglobulins labeled with dextran mole-
cules-alkaline phosphatase (Envision, Dako, Carpinteria,
CA, USA) at room temperature for 30 min. After three
washes with 0.04 M TBS pH 7.6 the reactions were devel-
oped using the new fuchsin kit (Kit New Fuchsin Substrate
System, Dako, Carpinteria, CA, USA) in the presence of
5 mM Levamisole (Sigma) to block endogenous alkaline
phosphatase. Negative staining controls were performed
either by omitting the primary antibody or using a control
isotype-matched antibody. Slides were counterstained
with hematoxylin and mounted in glycerol gel. All the sam-
ples were analyzed using a Zeiss Axioscope Microscope
(Carl Zeiss, Oberkochen, Germany).IMMUNOHISTOCHEMISTRY: TOTAL PROTEOGLYCANS
For immunohistochemical staining of proteoglycans
tissue samples were deparafﬁnized and rehydrated, then
epitopes were unmasked by 20 min deep in 0.02 U/ml
Chondroitinase ABC in TriseHCl pH 8 at 37C (Sigma). Af-
ter washes in 0.04 M TBS, tissue sections were blocked
with 5% NGS in 1X PBS, 30 min at room temperature.
The slides were then exposed to monoclonal mouse anti-
adult cartilage proteoglycans (Chemicon) antibody diluted
1:50 in 0.04 M TBSþ 1% BSA for 1 h at room temperature.
The antibody recognizes short peptides on the core protein
of proteoglycans of human articular cartilage. After washes,
incubation with goat anti-rabbit/mouse labeled with alkaline
phosphatase (Envision, Dako) was performed and ﬁnally
the reactions were developed using the new fuchsin kit
in the presence of 5 mM Levamisole (Sigma) to block
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trols were performed either by omitting the primary antibody
or using a control isotype-matched antibody. The slides
were counterstained with hematoxylin and mounted in glyc-
erol gel.
IMMUNOHISTOCHEMISTRY: CHONDROITIN-6-SULFATE
AND KERATAN SULFATE
After the samples had been deparafﬁnized and rehy-
drated, the epitopes were unmasked by 20 min deep in
0.02 U/ml Chondroitinase ABC in TriseHCl pH 8 at 37C
(Sigma). After the washes and the block of non-speciﬁc
binding, as reported above, an incubation of 90 min at
4C with anti-chondroitin-6-sulfate and anti-keratan sulfate
antibodies (Chemicon) diluted 1:100 in 0.04 M TBSþ 3%
normal rabbit serum (NRS) was performed. After further
washes, a Rabbit Anti-Mouse TRITC (Tetramethyl-rhoda-
mine-isothiocyanate, Dako) conjugated secondary antibody
was added to the slides for the detection of chondroitin-
6-sulfate, while a Rabbit Anti-Mouse FITC (Fluoresceine
isothiocyanate) conjugated secondary antibody was added
to the slides for the detection of keratan sulfate. Both the
antibodies were diluted 1:40 in 0.04 M TBSþ 3% NRS for
30 min at room temperature. Negative staining controls
were performed either by omitting the primary antibody or
using a control isotype-matched antibody. After two washes
the slides were mounted with an anti-fading solution (1,4
diazobicyclo 2.2.2. octane, Sigma) and visualized with
a ﬂuorescent microscope (Zeiss Axioscope microscope,
Carl Zeiss).
Results
SPECIFIC GENES mRNA EXPRESSION
Real-Time PCR allowed rapid and sensitive detection of
the extracellular matrix molecule mRNAs evaluated. Type
I collagen mRNA levels were higher in the patient samples
analyzed with respect to controls. Type II collagen mRNA
expression was lower in the patient samples than in the
controls. Aggrecan mRNA showed lower levels compared
to controls (Fig. 1).
HISTOCHEMISTRY
Cartilage from patients with Morquio syndrome [Fig. 2(A)]
showed a poorly organized morphological tissue structure,
both in the superﬁcial layer and in the deep zone. The cells
were not homogeneously distributed and larger than normal
chondrocytes [Fig. 2(B)], due to the presence of not metab-
olized proteoglycans inside the vacuoles. The collagen ﬁ-
bers were tangentially oriented in the superﬁcial layer of
the tissue but thicker. The tidemark was not well evident.
IMMUNOHISTOCHEMISTRY
In the cartilage from Morquio patients chondrocyte cells
were positive for collagen II staining at superﬁcial layers
and the extracellular matrix was weakly positive [Fig. 3(A)
and (B)], while control samples showed a strong positivity
both at cellular [Fig. 3(C)] and extracellular levels [Fig. 3(D)].
Conversely, collagen type I immunostaining was positive at
cellular level in both the superﬁcial and deep zones (Fig. 4).
Total proteoglycans were highly positive inside the cells
and in the extracellular matrix (Fig. 5). This positivity wasmore intense compared to healthy controls (data not shown).
Keratan sulfate showed a diffuse positivity (Fig. 6), as ob-
served for chondroitin-6-sulfate, while the controls showed
a light positivity (data not shown). It was possible to observe
a weak positivity also in the healthy controls, mainly localized
in the fundamental substance of the intermedial zone and the
pericellular one (data not shown).
Discussion
The data obtained in our study showed proteoglycan ac-
cumulation in the articular cartilage of patients suffering
from Morquio disease. This was particularly evident for
Fig. 4. Immunostaining for collagen type I shows a great positivity at
cellular level both in the superﬁcial and in the deep zones (A)
(bar¼ 200 mm). The control tissue is negative (B) (bar¼ 320 mm).
Collagen type I was developed using new fuchsine (red is positive
stain).
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present not only in the deep zones of the tissue, but also
at the superﬁcial layers, where they are usually scarcely
represented. This accumulation may be responsible for
some of the problems that affect people with the severe
form of the disease20. For a good performance of the artic-
ulation, in fact, proteoglycan concentration must be main-
tained constant21. The molecular and histological features
found in our patients were in agreement with the genetic in-
vestigations that have shown the presence of a mutation of
the gene which encodes for GALNS22, the enzyme res-
ponsible for the catabolic pathway of proteoglycans. The
immunohistochemical analysis, which showed that the
Fig. 5. Immunostaining for total proteoglycans is highly positive in-
side the cells and in the extracellular matrix also at the superﬁcial
layer (A) (bar ¼ 200 mm). The control shows a normal staining
and the superﬁcial layer is almost negative (B) (bar¼ 200 mm). Pro-
teoglycans were developed using new fuchsine (red is positive
stain).accumulation was localized in particular inside intracellular
vacuoles (the site of the GALNS enzyme), supported this
hypothesis. However, molecular evaluation showed that
the expression of aggrecan mRNA was lower compared
to that of healthy controls. This is not unusual since the ho-
meostasis of the cartilaginous tissue is regulated by a feed-
back mechanism in which chondrocytes increase the
proteoglycans’ production after loss of matrix23. On this
same basis, the cells might downregulate the expression
of the gene which encodes for aggrecan following an in-
crease in proteoglycans. An interesting ﬁnding was also
the low expression of collagen type II both at protein and
molecular levels. As known, collagen type II is universally
recognized as molecular marker of hyaline cartilage pheno-
type, since it is the main constituent among cartilage
Fig. 6. Immunostaining for keratan sulfate showed a diffuse positivity
(A) (bar¼ 200 mm), while the control is negative (B) (bar¼ 200 mm).
The image was acquired under green ﬂuorescence and shows only
those nuclei that are positive.
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such as tensile strength and traction forces24. The reduction
in ankle and knee joint movement, which is observable in
patients with Morquio disease, is therefore due to several
factors and not only to proteoglycan accumulation. The
high amount of collagen type I and the scarce presence
of collagen type II ﬁbers might be one of the causes. In Mor-
quio disease an inversion of the characteristic cartilaginous
pattern can be seen, with a higher percentage of collagen
type I compared to type II.
The histological and molecular analyses performed in this
study increased our knowledge about the etiopathogenesis
of MPS IV, highlighting the involvement of other factors be-
sides those already demonstrated. This could open new
therapeutic approaches as an alternative to surgery, which
is currently the only way to treat the skeletal abnormalities
caused by this pathology. In particular, on the basis of re-
cent signiﬁcant advances in recombinant DNA technology,
gene therapy, the insertion of genes into the cells or tissues
to modulate gene expression25, may represent in the future
an interesting approach to treat patients affected by
Morquio syndrome.
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